Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
Creator
Chen, Bing
Zhang, Jun
Alter, Galit
Ryan, Edward
Charles, Richelle
Cai, Yongfei
Caradonna, Timothy
Feldman, Jared
Gilboa, Tal
Hauser, Blake
Norman, Maia
Schmidt, Aaron
Walt, David
Cohen, Limor
Maley, Adam
Ogata, Alana
Source
MedRxiv; Medline
abstract
The COVID-19 pandemic continues to infect millions of people worldwide. In order to curb its spread and reduce morbidity and mortality, it is essential to develop sensitive and quantitative methods that identify infected individuals and enable accurate population-wide screening of both past and present infection. Here we show that Single Molecule Array assays detect seroconversion in COVID-19 patients as soon as one day after symptom onset using less than a microliter of blood. This multiplexed assay format allows us to quantitate IgG, IgM and IgA immunoglobulins against four SARS-CoV-2 targets, thereby interrogating 12 antibody isotype-viral protein interactions to give a high resolution profile of the immune response. Using a cohort of samples collected prior to the outbreak as well as samples collected during the pandemic, we demonstrate a sensitivity of 86% and a specificity of 100% during the first week of infection, and 100% sensitivity and specificity thereafter. This assay should become the gold standard for COVID19 serological profiling and will be a valuable tool for answering important questions about the heterogeneity of clinical presentation seen in the ongoing pandemic.
has issue date
2020-05-02
(
xsd:dateTime
)
bibo:doi
10.1101/2020.04.28.20083691
bibo:pmid
32511657
has license
medrxiv
sha1sum (hex)
122c9e7215ad5b79425da2ac3972ac57259949ae
schema:url
https://doi.org/10.1101/2020.04.28.20083691
resource representing a document's title
Ultra-Sensitive High-Resolution Profiling of Anti-SARS-CoV-2 Antibodies for Detecting Early Seroconversion in COVID-19 Patients
has PubMed identifier
32511657
schema:publication
medRxiv : the preprint server for health sciences
resource representing a document's body
covid:122c9e7215ad5b79425da2ac3972ac57259949ae#body_text
is
schema:about
of
named entity 'sensitive'
named entity 'prior'
named entity 'IgM'
named entity 'infection'
named entity 'infection'
named entity 'Profiling'
named entity 'Molecule'
named entity 'antibody'
named entity 'accurate'
named entity 'immunoglobulins'
named entity 'infect'
named entity 'Array'
named entity 'profiling'
named entity 'morbidity'
named entity 'quantitate'
named entity 'serological'
named entity 'assay'
named entity 'multiplexed'
named entity 'symptom'
named entity 'microliter'
named entity 'Antibodies'
named entity 'Seroconversion'
named entity 'immunoglobulins'
named entity 'morbidity'
named entity 'COVID19'
named entity 'COVID'
named entity 'IgM'
named entity 'week'
named entity 'COVID'
named entity 'viral protein'
named entity 'IgG'
named entity 'heterogeneity'
named entity 'quantitative methods'
named entity 'infection'
named entity 'SARS-CoV-2'
named entity 'COVID-19 pandemic'
named entity 'High-Resolution'
named entity 'Molecule'
covid:arg/122c9e7215ad5b79425da2ac3972ac57259949ae
named entity 'seroconversion'
named entity 'antibody isotype'
named entity 'infection'
named entity 'gold standard'
named entity 'clinical presentation'
named entity 'sensitivity and specificity'
named entity 'Ultra-Sensitive'
named entity 'assay'
named entity 'immune response'
named entity 'IgA'
named entity 'SARS-CoV-2'
named entity 'high'
named entity 'sensitivity'
named entity 'identify'
named entity 'quantitative methods'
named entity 'order'
named entity 'develop'
named entity 'pandemic'
named entity 'outbreak'
named entity 'protein'
named entity 'IgG'
named entity 'samples'
named entity 'targets'
named entity 'heterogeneity'
named entity 'demonstrate'
named entity 'tool'
named entity 'This'
named entity 'sensitivity'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 2
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software